Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 5.78
CYNO's Cash to Debt is ranked higher than
57% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. CYNO: 5.78 )
Ranked among companies with meaningful Cash to Debt only.
CYNO' s 10-Year Cash to Debt Range
Min: 2.24  Med: 85.78 Max: N/A
Current: 5.78
Equity to Asset 0.78
CYNO's Equity to Asset is ranked higher than
72% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. CYNO: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
CYNO' s 10-Year Equity to Asset Range
Min: 0.48  Med: 0.80 Max: 0.87
Current: 0.78
0.48
0.87
F-Score: 6
Z-Score: 6.33
M-Score: -2.38
WACC vs ROIC
2.24%
14.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 7.20
CYNO's Operating margin (%) is ranked higher than
63% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. CYNO: 7.20 )
Ranked among companies with meaningful Operating margin (%) only.
CYNO' s 10-Year Operating margin (%) Range
Min: -27.9  Med: -2.21 Max: 15.75
Current: 7.2
-27.9
15.75
Net-margin (%) 10.04
CYNO's Net-margin (%) is ranked higher than
78% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. CYNO: 10.04 )
Ranked among companies with meaningful Net-margin (%) only.
CYNO' s 10-Year Net-margin (%) Range
Min: -31.25  Med: -0.78 Max: 12.72
Current: 10.04
-31.25
12.72
ROE (%) 8.86
CYNO's ROE (%) is ranked higher than
66% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. CYNO: 8.86 )
Ranked among companies with meaningful ROE (%) only.
CYNO' s 10-Year ROE (%) Range
Min: -23.98  Med: -0.63 Max: 48.3
Current: 8.86
-23.98
48.3
ROA (%) 6.94
CYNO's ROA (%) is ranked higher than
74% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: -0.33 vs. CYNO: 6.94 )
Ranked among companies with meaningful ROA (%) only.
CYNO' s 10-Year ROA (%) Range
Min: -14.3  Med: -0.51 Max: 22.91
Current: 6.94
-14.3
22.91
ROC (Joel Greenblatt) (%) 24.05
CYNO's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. CYNO: 24.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYNO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -62.49  Med: 9.10 Max: 60.47
Current: 24.05
-62.49
60.47
Revenue Growth (3Y)(%) 14.40
CYNO's Revenue Growth (3Y)(%) is ranked higher than
82% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. CYNO: 14.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYNO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -13  Med: 14.40 Max: 24.8
Current: 14.4
-13
24.8
EBITDA Growth (3Y)(%) 64.90
CYNO's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. CYNO: 64.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYNO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -74.3  Med: 15.95 Max: 86.6
Current: 64.9
-74.3
86.6
» CYNO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CYNO Guru Trades in Q2 2014

Jim Simons 32,271 sh (New)
Mario Gabelli 20,250 sh (unchged)
Chuck Royce 253,500 sh (unchged)
Paul Tudor Jones 14,666 sh (-94.34%)
» More
Q3 2014

CYNO Guru Trades in Q3 2014

Chuck Royce 256,500 sh (+1.18%)
Jim Simons Sold Out
Paul Tudor Jones 13,472 sh (-8.14%)
Mario Gabelli 13,828 sh (-31.71%)
» More
Q4 2014

CYNO Guru Trades in Q4 2014

Paul Tudor Jones 14,829 sh (+10.07%)
Chuck Royce 240,900 sh (-6.08%)
Mario Gabelli 11,828 sh (-14.46%)
» More
Q1 2015

CYNO Guru Trades in Q1 2015

Jim Simons 124,274 sh (New)
Paul Tudor Jones 22,583 sh (+52.29%)
Chuck Royce 237,700 sh (-1.33%)
Mario Gabelli 11,406 sh (-3.57%)
» More
» Details

Insider Trades

Latest Guru Trades with CYNO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.00
CYNO's P/E(ttm) is ranked higher than
53% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 29.20 vs. CYNO: 28.00 )
Ranked among companies with meaningful P/E(ttm) only.
CYNO' s 10-Year P/E(ttm) Range
Min: 5.41  Med: 34.74 Max: 670.43
Current: 28
5.41
670.43
Forward P/E 20.58
CYNO's Forward P/E is ranked higher than
57% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.31 vs. CYNO: 20.58 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.90
CYNO's PE(NRI) is ranked higher than
53% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 29.20 vs. CYNO: 27.90 )
Ranked among companies with meaningful PE(NRI) only.
CYNO' s 10-Year PE(NRI) Range
Min: 5.42  Med: 34.58 Max: 630.2
Current: 27.9
5.42
630.2
P/B 2.35
CYNO's P/B is ranked higher than
60% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. CYNO: 2.35 )
Ranked among companies with meaningful P/B only.
CYNO' s 10-Year P/B Range
Min: 0.46  Med: 1.77 Max: 4.96
Current: 2.35
0.46
4.96
P/S 2.79
CYNO's P/S is ranked higher than
54% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. CYNO: 2.79 )
Ranked among companies with meaningful P/S only.
CYNO' s 10-Year P/S Range
Min: 0.5  Med: 2.08 Max: 5.83
Current: 2.79
0.5
5.83
PFCF 35.60
CYNO's PFCF is ranked lower than
61% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 31.27 vs. CYNO: 35.60 )
Ranked among companies with meaningful PFCF only.
CYNO' s 10-Year PFCF Range
Min: 8.7  Med: 26.30 Max: 164.91
Current: 35.6
8.7
164.91
POCF 22.43
CYNO's POCF is ranked higher than
50% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 22.43 vs. CYNO: 22.43 )
Ranked among companies with meaningful POCF only.
CYNO' s 10-Year POCF Range
Min: 5.75  Med: 20.81 Max: 787.75
Current: 22.43
5.75
787.75
EV-to-EBIT 34.79
CYNO's EV-to-EBIT is ranked lower than
69% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 22.74 vs. CYNO: 34.79 )
Ranked among companies with meaningful EV-to-EBIT only.
CYNO' s 10-Year EV-to-EBIT Range
Min: -183  Med: 1.75 Max: 311.7
Current: 34.79
-183
311.7
Current Ratio 3.06
CYNO's Current Ratio is ranked higher than
55% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. CYNO: 3.06 )
Ranked among companies with meaningful Current Ratio only.
CYNO' s 10-Year Current Ratio Range
Min: 1.67  Med: 4.39 Max: 7.09
Current: 3.06
1.67
7.09
Quick Ratio 2.18
CYNO's Quick Ratio is ranked higher than
53% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. CYNO: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
CYNO' s 10-Year Quick Ratio Range
Min: 0.87  Med: 3.52 Max: 5.83
Current: 2.18
0.87
5.83
Days Inventory 162.57
CYNO's Days Inventory is ranked lower than
63% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 130.93 vs. CYNO: 162.57 )
Ranked among companies with meaningful Days Inventory only.
CYNO' s 10-Year Days Inventory Range
Min: 85.48  Med: 172.83 Max: 289.61
Current: 162.57
85.48
289.61
Days Sales Outstanding 54.18
CYNO's Days Sales Outstanding is ranked higher than
72% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 68.45 vs. CYNO: 54.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYNO' s 10-Year Days Sales Outstanding Range
Min: 42.42  Med: 62.42 Max: 92.51
Current: 54.18
42.42
92.51

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.26
CYNO's Price/Net Current Asset Value is ranked higher than
50% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 6.26 vs. CYNO: 6.26 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYNO' s 10-Year Price/Net Current Asset Value Range
Min: 0.73  Med: 2.51 Max: 4.96
Current: 6.26
0.73
4.96
Price/Tangible Book 4.17
CYNO's Price/Tangible Book is ranked higher than
52% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. CYNO: 4.17 )
Ranked among companies with meaningful Price/Tangible Book only.
CYNO' s 10-Year Price/Tangible Book Range
Min: 0.56  Med: 2.16 Max: 4.58
Current: 4.17
0.56
4.58
Price/Projected FCF 2.09
CYNO's Price/Projected FCF is ranked higher than
51% of the 101 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. CYNO: 2.09 )
Ranked among companies with meaningful Price/Projected FCF only.
CYNO' s 10-Year Price/Projected FCF Range
Min: 1.05  Med: 1.56 Max: 2.09
Current: 2.09
1.05
2.09
Price/Median PS Value 1.34
CYNO's Price/Median PS Value is ranked lower than
63% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 1.11 vs. CYNO: 1.34 )
Ranked among companies with meaningful Price/Median PS Value only.
CYNO' s 10-Year Price/Median PS Value Range
Min: 0.32  Med: 0.98 Max: 2.63
Current: 1.34
0.32
2.63
Price/Graham Number 2.25
CYNO's Price/Graham Number is ranked higher than
52% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 2.37 vs. CYNO: 2.25 )
Ranked among companies with meaningful Price/Graham Number only.
CYNO' s 10-Year Price/Graham Number Range
Min: 0.65  Med: 1.85 Max: 7.95
Current: 2.25
0.65
7.95
Earnings Yield (Greenblatt) (%) 2.90
CYNO's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. CYNO: 2.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYNO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 3.90 Max: 1687.3
Current: 2.9
0.3
1687.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:C9S.Germany,
Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as they expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.
» More Articles for CYNO

Headlines

Articles On GuruFocus.com
old newsletter Apr 10 2012 
Cynosure Reports Second Quarter 2009 Financial Results Jul 28 2009 
Cynosure Inc. (CYNO) CFO Timothy W Baker buys 2,500 Shares Feb 27 2009 
Cynosure Inc. (CYNO) CEO Michael R Davin buys 2,500 Shares Feb 27 2009 
Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 Feb 10 2009 
Cynosure: A Value Play on Vanity Jan 18 2009 

More From Other Websites
Edited Transcript of CYNO earnings conference call or presentation 28-Jul-15 1:00pm GMT Jul 28 2015
Cynosure Inc Earnings Call scheduled for 9:00 am ET today Jul 28 2015
Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from... Jul 28 2015
Cynosure beats Street 2Q forecasts Jul 28 2015
Cynosure beats Street 2Q forecasts Jul 28 2015
CYNOSURE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 28 2015
Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from... Jul 28 2015
Q2 2015 Cynosure Inc Earnings Release - Before Market Open Jul 28 2015
A Timeless Lesson For Finding Double-Digit Winners Jul 17 2015
Cynosure to Host Second-Quarter 2015 Financial Results Conference Call on July 28 Jul 14 2015
Cynosure to Host Second-Quarter 2015 Financial Results Conference Call on July 28 Jul 14 2015
Cynosure Receives Expanded FDA 510(k) Clearance To Market SculpSure™ for Non-Invasive Lipolysis of... Jul 07 2015
Cynosure Receives Expanded FDA 510(k) Clearance To Market SculpSure™ for Non-Invasive Lipolysis of... Jul 07 2015
Cynosure Targets Raised At Northland Capital On Potential Vaginal Atrophy Treatment Jun 25 2015
New Website Helps Women Find Innovative Laser Treatment for Post-Menopause Symptoms May 27 2015
New Website Helps Women Find Innovative Laser Treatment for Post-Menopause Symptoms May 27 2015
6 stocks to watch May 20 2015
Cynosure Receives FDA 510(k) Clearance for SculpSure™, the World's First Hyperthermic Laser... May 19 2015
Cynosure Receives FDA 510(k) Clearance for SculpSure™, the World's First Hyperthermic Laser... May 19 2015
CYNOSURE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK